Abstract: Disclosed is a method for determining a mixing temperature of an asphalt mixture which includes the following steps: S100, obtaining a test result of surface energy of hot-melt asphalt; S200, obtaining, according to a calculation formula for total adhesion work and in combination with the test result of the surface energy of the hot-melt asphalt, total adhesion work of an asphalt and aggregate interface at different mixing temperatures; S300, determining a temperature range corresponding to peak values of the total adhesion work of the asphalt and aggregate interface; and S400, calculating a median value of the temperature range determined in S300, so as to determine an optimum mixing temperature of the asphalt mixture.

Abstract: The disclosure provides, among other things, methods and uses for treating a disease or disorder, particularly a cancer, in a patient, comprising conjointly administering a CTLA4 inhibitor (e.g., an anti-CTLA4 antibody) and a STING agonist to the patient, wherein the CTLA4 inhibitor is administered intratumorally to the patient. The STING agonist can be administered intratumorally, orally or systemically (e.g., intravenously, intramuscularly, or subcutaneously) to the patient.

Abstract: A treatment for reducing glucose bioaccessibility can include providing a superabsorbent material that includes a porous network structure formed from a mixture of a plurality of water soluble polysaccharides that are not chemically crosslinked together. The superabsorbent material can be administered to a subject in an effective amount to reduce glucose bioaccessibility in the subject. In some aspects, the treatment for reducing glucose bioaccessibility with the superabsorbent material retains a substantially unaltered fatty acid bioaccessibility and/or retains a substantially unaltered protein bioaccessibility.

Abstract: Provided are superabsorbent materials composed of one or more water-soluble polysaccharides, such as gelling polysaccharides and gelling-compatible polysaccharides, and one or more insoluble fibers. The disclosed superabsorbent materials have a porous network structure and highly stable gelling properties as well as high absorption ratio and volume expansion capacity upon hydration or rehydration. Also provided are methods for preparing such superabsorbent materials and uses thereof.

Abstract: The present disclosure relates to, among other things, antibody-drug conjugates comprising a STING agonist cyclic di-nucleotide conjugated to an antibody, preparation methods therefor, and uses therefor.

Abstract: Provided are superabsorbent materials composed of agar, and one or more water-soluble natural polysaccharides, and dietary compositions containing such superabsorbent materials. The disclosed superabsorbent materials have various food and therapeutic applications and can be used as loading vehicles for nutrients and therapeutic agents. Also provided are methods for preparing such superabsorbent materials.

Abstract: A treatment for obesity can include: providing a superabsorbent material that includes a porous network structure formed from a mixture of a plurality of water soluble polysaccharides that are not chemically crosslinked together; and administering the superabsorbent material to a subject in an effective amount to provide a treatment for obesity in the subject. The treatment can include at least one of: reducing weight of the subject; reducing rate of weight gain in the subject; or increasing rate of weight loss in the subject. The treatment of obesity can include at least one of: reducing caloric intake into the subject; reducing caloric absorption by the gut of the subject; absorbing caloric material from the gut of the subject into the superabsorbent material; or increasing transfer of caloric material from bloodstream into gut.

Abstract: Methods for reducing cholesterol in a subject can include: providing a superabsorbent material that includes a porous network structure formed from a mixture of a plurality of water soluble polysaccharides that are not chemically crosslinked together; and administering the superabsorbent material to a subject in an effective amount to reduce cholesterol in the subject. The reduction of cholesterol includes at least one of: reducing total cholesterol of the subject; reducing a rate of total cholesterol increase in the subject; or increasing a rate of total cholesterol decrease in the subject. The reduction of cholesterol includes at least one of: reducing cholesterol intake into the subject; reducing cholesterol absorption by the gut of the subject; or absorbing cholesterol material from the gut of the subject into the superabsorbent material. The reduction of cholesterol is by reduction of low-density-lipoprotein cholesterol or high-density-lipoprotein cholesterol.

Abstract: Provided are superabsorbent materials composed of one or more water-soluble polysaccharides, such as gelling polysaccharides and gelling-compatible polysaccharides, and one or more insoluble fibers. The disclosed superabsorbent materials have a porous network structure and highly stable gelling properties as well as high absorption ratio and volume expansion capacity upon hydration or rehydration. Also provided are methods for preparing such superabsorbent materials and uses thereof.

Abstract: Provided are superabsorbent materials composed of one or more water-soluble polysaccharides, such as gelling polysaccharides and gelling-compatible polysaccharides, and one or more insoluble fibers. The disclosed superabsorbent materials have a porous network structure and highly stable gelling properties as well as high absorption ratio and volume expansion capacity upon hydration or rehydration. Also provided are methods for preparing such superabsorbent materials and uses thereof.

Abstract: Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders associated with mast cells. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more diseases and disorders associated with mast cells.

Abstract: Provided are superabsorbent materials composed of agar, and one or more water-soluble natural polysaccharides, and dietary compositions containing such superabsorbent materials. The disclosed superabsorbent materials have various food and therapeutic applications and can be used as loading vehicles for nutrients and therapeutic agents. Also provided are methods for preparing such superabsorbent materials.

Abstract: The present disclosure relates to, among other things, antibody-drug conjugates comprising a STING agonist cyclic di-nucleotide conjugated to an antibody, preparation methods therefor, and uses therefor.

Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: An insulating container comprises a container body and a container cover connected to the container body. The container body and the container cover each comprises a frame and a plate arranged on the frame. The plate comprises, from inside out, an external high strength sheet, an extruded polystyrene sheet, phase-change insulating sheets made of phase-change material, and an internal sheet. A phase-change process of the phase-change insulating sheets cooperates with a refrigeration system of the transportation device to precisely control the temperature of the insulating container and a refrigerator truck to be near a phase-change temperature. In the present disclosure, the phase-change insulating sheets made of the phase-change material remain to be in a solid state before or after occurrence of a phase change, so that the structure of the insulating container does not change with the phase change and a leakage problem of the phase-change material does not exist.

Abstract: Provided are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, tautomers, isotopically labeled derivatives, polymorphs, and prodrugs thereof, wherein X1-X4, RX, RC, RB, n, and Ring A are as defined herein. The compounds may be aryl hydrocarbon receptor agonists or partial aryl hydrocarbon receptor agonists. Also provided are pharmaceutical compositions comprising a compound of Formula (I) and methods of using such compounds for treating diseases and conditions related to the activity of an aryl hydrocarbon receptor, such as, for example, inflammatory diseases, autoimmune diseases, metabolic disorders, and proliferative diseases.

Abstract: The present invention provides a method for preparing a hot-mixed asphalt mixture, and relates to the technical field of road engineering. In the present invention, asphalt and aggregates are preheated separately, where the aggregates include coarse aggregates and fine aggregates; the coarse aggregates, part of the fine aggregates and asphalt that are preheated are subjected to a first mixing to obtain a first mixture; the remaining fine aggregates are added to the first mixture for a second mixing to obtain a second mixture; and a mineral powder is added to the second mixture for a third mixing, and discharging is conducted to obtain a hot-mixed asphalt mixture.

Abstract: Disclosed are novel compounds of Formula I that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Abstract: An insulating container comprises a container body and a container cover connected to the container body. The container both and the container cover each comprises a frame and a plate arranged on the frame. The plate comprises, from inside out, an external high strength sheet, an extruded polystyrene sheet, phase-change insulating sheets made of phase-change material, and an internal sheet. A phase-change process of the phase-change insulating sheets cooperates with a refrigeration system of the transportation device to precisely control the temperature of the insulating container and a refrigerator truck to be near a phase-change temperature. In the present disclosure, the phase-change insulating sheets made of the phase-change material remain to be in a solid state before or after occurrence of a phase change, so that the structure of the insulating container does not change with the phase change and a leakage problem of the phase-change material does not exist.

Abstract: The present disclosure relates to, among other things, antibody-drug conjugates comprising a STING agonist cyclic di-nucleotide conjugated to an antibody, preparation methods therefor, and uses therefor.